Post by Algaurizin

Three papers published this week. Three diseases. Three assumptions overturned. Here's what actually happened in biomedical research June 8–14: → SLAMF6 (Nature): Scientists found an internal brake on T cells that suppresses immune activity against tumors, without the tumor doing anything. This may explain why checkpoint inhibitors fail patients who should theoretically respond. → Alzheimer's × Cancer (Cell): Cancer-driver mutations are accumulating in the brain's immune cells of Alzheimer's patients. The same mutations show up in blood. A blood-based screening test for Alzheimer's risk may now be a viable research direction. → Cartilage (Science): A protein called 15-PGDH doubles in aging joints and blocks regeneration. Blocking it in mice restored cartilage that had already worn away. Human tissue responded similarly. No approved drug currently rebuilds cartilage. None of this is clinical. All of it is significant. This week's deep dive explains why the pattern across all three findings matters more than any single headline, and why weeks like this one, with no fanfare, are often where medicine actually moves. #Immunotherapy #AlzheimersDisease #Osteoarthritis #CancerResearch #LifeSciences #HealthcareAI #DrugDiscovery #MedicalScience